(Q44743198)

5 December 2017

A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus (English)

1 reference

5 December 2017

1 reference

1 reference

1 reference

8

Charles S Fuchs

1 reference

5 December 2017

Matthew H Kulke

1

1 reference

5 December 2017

Bingyan Wu

2

1 reference

5 December 2017

Jeffrey W Clark

3

1 reference

5 December 2017

Peter C Enzinger

4

1 reference

5 December 2017

Thomas J Lynch

5

1 reference

5 December 2017

Michele Vincitore

6

1 reference

5 December 2017

Ann Michelini

7

1 reference

5 December 2017

language of work or name

1 reference

1 April 2006

1 reference

5 December 2017

1 reference

5 December 2017

24

1 reference

5 December 2017

3

1 reference

5 December 2017

229-234

1 reference

5 December 2017

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1080%2F07357900600633924

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600633924

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600633924

Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600633924

A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600633924

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600633924

Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600633924

CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600633924

Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600633924

Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600633924

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600633924

Epirubicin, cisplatin, and fluorouracil in gastric and esophageal cancer: a step ahead?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600633924

Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600633924

A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600633924

Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900600633924

10.1080/07357900600633924

21 January 2018

Identifiers

DOI

1 reference

5 December 2017

1 reference